Multiple sclerosis is a complex neurological disease, with $20% of risk heritability attributable to common genetic variants, including >230 identified by genome-wide association studies. Multiple strands of evidence suggest that much of the remaining heritability is also due to additive effects of common variants rather than epistasis between these variants or mutations exclusive to individual families. Here, we show in 68,379 cases and controls that up to 5% of this heritability is explained by low-frequency variation in gene coding sequence. We identify four novel genes driving MS risk independently of common-variant signals, highlighting key pathogenic roles for regulatory T cell homeostasis and regulation, IFNg biology, and NFkB signaling. As low-frequency variants do not show substantial linkage disequilibrium with other variants, and as coding variants are more interpretable and experimentally tractable than non-coding variation, our discoveries constitute a rich resource for dissecting the pathobiology of MS.
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In a large multi-cohort study, unexplained heritability for multiple sclerosis is detected in low-frequency coding variants that are missed by GWAS analyses, further underscoring the role of immune genes in MS pathology. 
INTRODUCTION
Multiple sclerosis (MS; MIM 126200) is an autoimmune disease of the central nervous system and a common cause of neurologic disability in young adults (Compston and Coles, 2008) . It is most prevalent in individuals of northern European ancestry and-in line with other complex, common disorders-shows substantial heritability (Binder et al., 2016) , with a sibling standardized incidence ratio of 7:1 (Westerlind et al., 2014) . Over the last 15 years, we have identified 233 independent, common-variant associations mediating disease risk by genomewide association studies (GWASs) of increasing sample size (Andlauer et al., 2016; Australia and New Zealand Multiple Sclerosis Genetics Consortium, 2009; Baranzini et al., 2009; Beecham et al., 2013; De Jager et al., 2009; International Multiple Sclerosis Genetics Consortium et al., 2011 Jakkula et al., 2010; Martinelli-Boneschi et al., 2012; Nischwitz et al., 2010; Patsopoulos et al., 2011; Sanna et al., 2010; Burton et al., 2007) . In our most recent meta-analysis of 14,802 MS cases and 26,703 controls, these effects-including 32 mapping to classical human leukocyte antigen (HLA) alleles and other variation in the major histocompatibility (MHC) locus (International Multiple Sclerosis Genetics Consortium et al., 2017; Moutsianas et al., 2015; Patsopoulos et al., 2013) -account for 7.5% of h 2 g, the heritability attributable to additive genetic effects captured by genotyping arrays, with a total of 19.2% of h2g attributable to all common variants in the autosomal genome (International Multiple Sclerosis Genetics Consortium et al., 2017) . MS is thus a prototypical complex disease with a substantial portion of heritability determined by hundreds of common genetic variants, each of which explain only a small fraction of risk (Sawcer et al., 2014) . As with other common, complex diseases where large GWASs have been conducted, we find that although common variants (minor allele frequency [MAF] > 5%) account for the bulk of trait heritability, they cannot account for its entirety. Identifying the source of this unexplained heritability has thus become a major challenge (Manolio et al., 2009) . Two hypotheses are frequently advanced: some common variants show epistatic (i.e., nonadditive) interactions so that they contribute more risk in combination than each does alone, and a portion of risk is due to rare variants that cannot be imputed via linkage disequilibrium to common variants present on genotyping arrays and are therefore invisible to heritability calculations based on such arrays. The only evidence we have found for epistatic interactions between common MS risk variants is between two HLA haplotype families in the MHC locus (Moutsianas et al., 2015) . This lack of epistatic interactions is consistent with other common, complex diseases, both of the immune system and beyond (Altshuler et al., 2008) . We have also found no evidence that mutations in individual families drive disease risk in genome-wide linkage analyses of 730 MS families with multiple affected members (Sawcer et al., 2005) . These results indicate that neither epistasis between known risk variants nor mutations in a limited number of loci are major sources of MS risk. They do not, however, preclude a role for variants present in the population at low frequencies, which cannot be imputed but are likely to individually contribute moderate risk.
Here, we report our assessment of the contribution of lowfrequency variation in gene coding regions to MS risk. We conducted a meta-analysis of 120,991 low-frequency coding variants across all autosomal exons, including 104,218 non-synonymous and 2,276 nonsense variants, which are more likely to have a phenotypic effect. We analyzed a total of 32,367 MS cases and 36,012 controls drawn from centers across Australia, 10 European countries, and multiple US states, which we genotyped either on the Illumina HumanExome Beadchip (exome chip) or on a custom array (the MS chip), incorporating the exome chip content (International Multiple Sclerosis Genetics Consortium et al., 2017) , and which satisfied our stringent quality control filters ( Figure S1 and Table S1 ). The exome array is a cost-efficient alternative to exome sequencing, capturing approximately 88% of low-frequency and rare-coding variants present in 33,370 non-Finnish Europeans included in the Exome Aggregation Consortium (MAFs between 0.0001 and 0.05; Figure S1) , and <5% of the extremely rare alleles present at even lower frequencies. Our study was well powered, with 80% power to detect modest effects at low frequency (odds ratio [OR] = 1.15 at MAF = 5%) and rare variants (OR = 1.5 at MAF = 0.5%) at a significance threshold of p < 3.5 3 10 À7 (Bonferroni correction for the total number of variants genotyped).
RESULTS
We first assessed the contribution of individual variants to MS risk by conducting a meta-analysis of association statistics across 14 country-level strata ( Figure 1 and Table S1 ). We used linear mixed models to correct for population structure in (A-C) We analyzed 120,991 low-frequency non-synonymous coding variants across all autosomal exons in 32,367 MS cases and 36,012 controls drawn across the International Multiple Sclerosis Genetics Consortium centers. We find evidence for association with both common variants with combined MAF > 5% (A) and with rare variants across the autosomes (B). We sourced samples from Australia, 10 European countries, and the United States (C). See also Figures S2 and S3.
13 of these strata, estimated from the 16,066 common, synonymous coding variants present on the exome chip (i.e., variants with MAF > 5% in our samples). We included population structure-corrected summary statistics for the remaining cohort (from Germany), which has been previously described (Dankowski et al., 2015) . As expected, we saw a strong correlation between effect size and variant frequency, with rarer alleles exerting larger effects ( Figure S2 ). We found significant association between MS risk and seven low-frequency coding variants in six genes outside the extended MHC locus on chromosome 6 (Table 1 and Figure S3) . Two of these variants (TYK2 p.Pro1104Ala, overall MAF 4.1% in our samples; GALC p.Asp84Asp, overall MAF 3.9%) are in regions identified by our latest MS GWAS and show linkage disequilibrium with the common-variant associations we have previously reported (International Multiple Sclerosis Genetics Consortium et al., 2011) . The remaining associations are novel, with the variants neither in linkage disequilibrium nor physical proximity to common variant association signals and thus not imputable in our GWASs (Table S2) .
We were struck by the observation that the minor allele is protective in six of the seven cases in Table 1 , a trend we also observe at less stringent significant thresholds ( Figure S2 ). This pattern is unusual in common-variant studies: for example, in our most recent GWAS, 101/200 non-MHC effects showed that the minor allele increases risk. To test if this phenomenon is due to our strata containing more cases than controls, we randomly resampled 4,000 affected and 4,000 unaffected samples in our three largest strata and calculated association statistics as for our main analysis. In this symmetric design, we found no bias toward protective minor alleles at even modest levels of significance (Table S3 ). Thus, low-frequency variants do not preferentially decrease MS risk rather than increase it.
Though we are able to identify individual low-frequency variants associated with MS risk, we recognize that we cannot detect all such variants at genome-wide significance, even in a study of this magnitude. We thus sought to quantify the overall contribution of low-frequency coding variation to MS risk. We used a restricted maximum-likelihood approach to model heritability attributable to genotypic variation across the genome that was initially developed for common-variant analyses (Yang et al., 2011) and later shown to also perform well for rare variants, as in the present case (Mancuso et al., 2016) . In each of the 13 strata that comprise our data, we estimated the proportion of heritability explained by common (MAF > 5%) and low-frequency (MAF % 5%; Table S4 ) variants on the exome arrays (Yang et al., 2011) . We included genotype-derived principal components to further control for population stratification. By meta-analyzing these estimates across the twelve strata where the restricted maximum likelihood model converged, we found that low-frequency variants explain 11.34% (95% confidence interval 11.33%-11.35%) of the observed difference between cases and controls (mean estimate 4.1% on the liability scale; Figure 2 ). We further partitioned the low-frequency variants into intermediate (5% > MAF R 1%) and rare (MAF < 1%) and found that the latter alone explain 9.0% (95% confidence interval 8.9%-9.1%) on the observed scale (mean estimate 3.2% on the liability scale; Figure 2 ). We note that six of the eight genome-wide significant variants presented in Table 1 are of intermediate frequency and thus are not included in the rare category. We capture the majority, though not all, of known common risk variants to some extent with the common variants on the exome chip (Table S5 ); our analysis therefore adequately, though imperfectly, models this portion of the frequency spectrum. Our results thus indicate that many more non-synonymous rare variants contribute to MS risk but are not individually detectable at genome-wide thresholds, even in large studies like ours.
In this study, we show that low-frequency coding variation explains a fraction of MS risk that cannot be attributed to common variants across the genome. We capture most, but not all, low-frequency missense variants ( Figure S1 ), suggesting our heritability estimates for low-frequency and rare variation are conservative. This broadly agrees with previous reports that such variants contribute to complex traits, including Alzheimer's disease (Sims et al., 2017) and schizophrenia (Purcell et al., 2014) , where heritability modeling similar to ours supports a role for rare variants. Studies of quantitative phenotypes shared by the entire population, such as height (Marouli et al., 2017) , serum lipid levels (Liu et al., 2017) , and blood cell traits (Chami et al., 2016; CHARGE Consortium Hematology Working Group, 2016) have also reported novel associations to low-frequency coding variants outside the large number of known GWAS loci in each trait. However, a meta-analysis of different type 2 We analyzed 120,991 low-frequency non-synonymous coding variants across all autosomal exons in 32,367 MS cases and 36,012 controls drawn from centers across Australia, 10 European countries, and multiple US states. Genome positions are relative to hg19. The two variants in PRKRA are in linkage disequilibrium (R 2 = 1, D' = 1 in the 1000 Genomes European samples). These variants lie in common variant risk loci found in our previous diabetes study designs found no associations outside commonvariant GWAS regions (Fuchsberger et al., 2016) , though this may be due to the heterogeneity of sample ascertainment and study design. In aggregate, therefore, our results and these past studies demonstrate that rare coding variants contribute a fraction of common, complex trait heritability. These results also agree with both theoretical expectation and empirical observations that low-frequency coding variants are under natural selection and are unlikely to increase in frequency in the population (Nelson et al., 2012; Schoech et al., 2017; Zeng et al., 2018) . Thus, some portion of disease-associated variants, and hence the genes they influence, may not be detectable with conventional GWAS designs. The newly discovered genes have clear immunological functions, confirming that MS pathogenesis is primarily driven by immune dysfunction. The associated polymorphisms show negligible linkage disequilibrium with other variants (Table S2) , so the genes harboring them are likely to be relevant to disease. PRF1 encodes perforin, a key component of the granzymemediated cytotoxicity pathways used by several lymphocyte populations. In addition to cytotoxic lymphocytes and natural killer (NK) cells (House et al., 2015) , perforin-dependent cytotoxicity is also seen in CD4 + FOXP3
+ regulatory T cells (Tregs), which show aberrant, T helper-like IFNg secretion in MS patients (Dominguez-Villar et al., 2011) . The MS risk variant rs35947132 (p.Ala91Val) is associated with a decrease in target cell-killing efficiency and increases in IFNg secretion by NK cells (House et al., 2015) , which aligns with the aberrant Treg phenotype observed in MS. This decreased cytotoxicity efficiency will prolong average cell-cell interactions with target cells, and such extended interactions are known to increase T cell-receptormediated signaling and induce changes to T cell phenotypes, especially secretion of IFNg and other cytokines (Constant et al., 1995 
Figure 2. Rare Variants Explain a Substantial Portion of Multiple Sclerosis Heritability
We estimated the MS risk heritability explained by common variants (MAF > 5%) and low-frequency non-synonymous coding variation (MAF < 5%) in each of 13 cohorts genotyped on the exome chip using genome-wide complex trait analysis (GCTA; top). By meta-analyzing these estimates across cohorts, we found that low-frequency variants explain 11.34% of heritability on the observed scale, which corresponds to 4.1% on the liability scale (right top). After dividing the lowfrequency variants into intermediate (5% > MAF > 1%) and rare (MAF < 1%; bottom), we found that the latter alone explains 9.0% heritability on the observed scale (3.2% on the liability scale; bottom right). Meta-analysis confidence intervals are small and visually occluded by the mean estimate plot characters. Cohorts (abbreviations as in Table S1 ) are ordered by sample size, with the percentage of the overall sample size shown in each subplot title. We could not obtain estimates for either model for our Finnish cohort (see STAR Methods; not shown), or for the three-component model for our Belgian cohort (bottom, top row, fourth from left). Both cohorts are small, which may explain the failure to converge.
deacetylase 7, which potentiates the repressive effects of FOXP3, the master regulator governing naive CD4 + T cell development into Tregs (Bettini et al., 2012; Li et al., 2007) . It also regulates T cell survival during their development in the thymus (Kasler et al., 2011) . PRKRA encodes protein kinase interferoninducible double-stranded RNA-dependent activator; in response to double-stranded RNA due to virus infection, it heterodimerizes with protein kinase R to inhibit EIF2a-dependent translation, resulting in upregulation of nuclear factor kB (NFkB) signaling, interferon production, and eventually, apoptosis (Sadler and Williams, 2008) . NFkB-mediated signaling is a core feature of MS pathogenesis, which we have shown to be altered by at least one MS-associated variant (Housley et al., 2015) and may be the relevant mechanism for this gene. Finally, NLRP8 is an intracellular cytosolic receptor active in innate immune responses; the Ile942Met MS risk variant rs61734100 is detected only in individuals with European ancestry in ExAC, consistent with the higher prevalence of MS in European ancestry populations.
DISCUSSION
Broadly, therefore, our results show that low-frequency genetic variation explains a portion of MS risk and that this variation impacts genes not detectable by common-variant association studies. Our heritability modeling demonstrates that more lowfrequency and rare-variant associations remain to be discovered, though larger sample sizes will be required to increase statistical power. Recent attention has focused on changes to the adaptive immune system as pathogenic for MS, particularly to functional changes in helper T cell subsets and B cells after they have been released from the thymus and bone marrow, respectively, into the peripheral blood stream. These processes remain important to pathogenesis and are supported by a wealth of data, including our own GWAS (International Multiple Sclerosis Genetics Consortium et al., 2017). However, two of the four new genes we report (PRKRA and NLRP8) have clear functions in innate immunity, and HDAC7 plays a central role in the development of T cells in the thymus. Roles for both innate immune function and thymic development in MS pathogenesis are also supported by pathway analyses of our most recent GWAS data (International Multiple Sclerosis Genetics Consortium et al., 2017), an independent observation due to the lack of linkage disequilibrium (LD) between the variants in this study and those in our GWAS and the non-overlapping sample collections. Our data thus expand the scope of immune function relevant to MS pathogenesis. The mechanisms whereby our newly discovered variants alter MS risk will require detailed experimental dissection: even when we can directly implicate specific genes and variants, these can have diverse consequences across multiple cell types. For example, perforin 1 has key-and potentially distinct-roles in cytotoxic T cells, regulatory helper T cells, NK cells, and other cell types. Both the effects of the variant on each of these functions and their relevance to MS pathogenesis will thus require demonstration, as is the case for the genes central to IFNg biology, Treg function, and the NFkB signaling pathway.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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Philip L De Jager has received honoraria for acting as a member of Scientific Advisory Boards for Sanofi/Genzyme, Celgene, Roche, and Biogen Idec; and has received research support from Biogen Idec, Roche and Genentech. MAF > 5%, or > 1% zCall missing data rate for variants with MAF < 5%. We also removed variants out of Hardy-Weinberg equilibrium (p < 10 À5 ). Next, we removed samples with high similarity in missing genotypes (''identity by missingness'') indicative of production artifact, and samples with missing phenotype information. Finally, we again removed any remaining population outliers using projection principal component analysis. We calculated 30 principal components for 1,092 individuals in 1000 Genomes reference populations, again using the 16,066 common variants in linkage disequilibrium (r 2 < 0.1) across the exome. We then projected the IMSGC samples into this space and excluded individuals more than six standard deviations from loading means as previously described (Price et al., 2006) . We performed the projection and outlier detection and removal steps a total ten times to gradually remove more subtle population outliers. We compiled cases and controls into strata for analysis as shown in Table S1 . In total, we removed 17,938/76,140 (24%) samples either due to low data quality or as population outliers, leaving a final dataset of 27,891 cases and 30,298 controls in 13 strata ( Figure S1 and Table S1 ). Separately, we included summary statistics from 4,476 MS cases and 5,714 controls from Germany, genotyped on the exome chip as previously described (Dankowski et al., 2015) , giving us a total of 32,367 MS cases and 36,012 controls for analysis.
QUANTIFICATION AND STATISTICAL ANALYSIS Exome chip coverage of ExAC variants
To assess how thoroughly the exome chip assesses low-frequency coding variation genome-wide, we compared it to the list of variants reported by the Exome Aggregation Consortium, ExAC (Lek et al., 2016) , in their data release version 1. We filtered their summary table of all ExAC variants (available at ftp://ftp.broadinstitute.org/pub/ExAC_release/release1/manuscript_data/ExAC.r1.sites. vep.table.gz and last accessed 15 November 2017) for nonsynonymous coding variants passing their quality control, with at least one minor allele observed in non-Finnish European samples. We identified which of these variants are represented on the exome chip by comparing genomic coordinates.
Univariate association analysis
We used mixed linear models for association analysis, as implemented in GCTA (Yang et al., 2011) . In each of our 13 genotype-level strata, we calculated genetic relatedness matrices from 16,066 common, noncoding variants (overall MAF > 0.05) in linkage equilibrium (all pairwise r 2 < 0.1) present on the exome chip, and with these calculated univariate association statistics for each autosomal variant present on the exome chip. To further control for population stratification, we also calculated genotypic principal components with the 16,066 common variants, and included these as covariates to the association analysis. We also included genotypic sex and chip type as covariates. We combined statistics across strata using inverse-variance-weighted meta-analysis, also as implemented in GCTA (Yang et al., 2011) . As the bulk of exome chip variants are not common and do not show appreciable linkage disequilibrium, we controlled for multiple tests with a Bonferroni correction for the number of low-frequency variants, to give a genome-wide significance threshold of p < 3.58 3 10e -7 (0.05/139,764 variants with a combined MAF < 0.05 in controls and a heterogeneity index I 2 < 50 in our meta-analysis).
Heritability estimation
We used GCTA to calculate the heritability attributable to groups of variants in each of our 13 genotype-level strata (Yang et al., 2011) . In each stratum, we ran two sets of models: a two-component model, estimating the heritability attributable to common and low-frequency (MAF % 0.05) variants; and a three component model with rare (MAF % 0.01), intermediate (0.01 < MAF % 0.05), and common variants. In all strata, common variants are the set of 16,066 independent variants (overall MAF > 0.05) used for population stratification calculations in the univariate analysis above. We computed genetic relatedness matrices for each component of each model, then calculated narrow-sense heritability (h 2 ) with 100 iterations of constrained restricted maximum likelihood (REML) fitting, assuming a disease prevalence of 0.001. We also included the principal components of population structure computed for the univariate analysis as covariates. As anticipated, several of the smaller cohorts presented fitting issues: no models converged for FIN; both three-component and two-component fits for UCSF2, and the three-component model for GRE would not converge under constraint and so were run without constraints; and the three-component model for BEL converged on two exactly equally likely solutions after 10,000 iterations. For the latter, we chose the most conservative estimates of variance explained. We combined these estimates with inverse variance-weighted meta-analysis.
DATA AND SOFTWARE AVAILABILITY
Meta-analysis summary statistics are available at http://imsgc.net/. Due to varying privacy laws across countries, some of our genotype data are available from the European Genome-phenome Archive (deposited under accession EGAS00001003195), with the remainder available directly from participating centers. A single request for all data access may be submitted to the IMSGC Data Access Committee (dac@imsgc.net). Our QC and analysis pipeline is available at https://github.com/cotsapaslab/ IMSGCexomechip. A) effect sizes increase at low minor allele frequency. We conducted a meta-analysis of 120,991 low-frequency coding variants across all autosomal exons, concentrating on non-synonymous variants which are more likely to have a phenotypic effect. We analyzed a total of 32,367 MS cases and 36,012 controls in thirteen strata. Here, we show that estimates of effect size (b or log odds ratio, y axis) increase at low allele frequency (number of minor alleles present in control samples, x axis). Because many low-frequency variants are not present in all cohorts, we stratify these data by number of cohorts in which a variant is polymorphic (subplots). Rarer variants have larger estimated effect sizes and are present in fewer cohorts. (B) forest plots for genome-wide significant low-frequency variants. Seven variants in six genes are significant in our analysis (p < 3.5 3 10 À7 , Bonferroni correction for the total number of variants genotyped). Two of these (TYK2 p.Pro1104Ala and GALC p.Asp84Asp), are in linkage disequilibrium with known GWAS hits. Studies are ordered by increasing sample size. Plots are centered on the seven variants reported in Figure 1 and Table 1 . Each show LD and association signal of low frequency variants (circles, this study), and common variants from our most recent GWAS (squares, 14,802 MS cases and 26,703 controls; International Multiple Sclerosis Genetics Consortium et al., 2017) and the ImmunoChip meta-analysis (diamonds; Beecham et al., 2013) . For GALC and TYK2, our most associated variants, rs11552556 and rs34536443 respectively, capture the common variant signals we have previously reported (panels A and G). For the remaining loci, our most associated variants show no LD to other variants, with no evidence of association in our common variant studies (panels B-F).
